text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 178306-52-0 | Product Number: H1568

(S)-2-Hydroxy-3-methoxy-3,3-diphenylpropionic Acid


Purity: >98.0%(T)(HPLC)
Synonyms:
Product Documents:
1G
94,00 €
1   4  
5G
327,00 €
1   3  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number H1568
Purity / Analysis Method >98.0%(T)(HPLC)
Molecular Formula / Molecular Weight C__1__6H__1__6O__4 = 272.30 
Physical State (20 deg.C) Solid
Storage Temperature Room Temperature (Recommended in a cool and dark place, <15°C)
CAS RN 178306-52-0
Reaxys Registry Number 8413483
PubChem Substance ID 354334235
MDL Number

MFCD11113284

Specifications
Appearance White to Almost white powder to crystal
Purity(GC) min. 98.0 %
Purity(Neutralization titration) min. 98.0 %
Specific rotation [a]20/D +11.0 to +15.0 deg(C=1.8, EtOH)
NMR confirm to structure
Properties (reference)
Melting Point 120 °C(dec.)
Specific Rotation 13° (C=1.8,EtOH)
GHS
Pictogram Pictogram
Signal Word Warning
Hazard Statements H315 : Causes skin irritation.
H319 : Causes serious eye irritation.
Precautionary Statements P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ eye protection/ face protection.
P302 + P352 : IF ON SKIN: Wash with plenty of water.
P337 + P313 : If eye irritation persists: Get medical advice/ attention.
P362 + P364 : Take off contaminated clothing and wash it before reuse.
P332 + P313 : If skin irritation occurs: Get medical advice/ attention.
Related Laws:
Transport Information:
HS Number 2918999090
Application
A Key Synthetic Intermediate of Ambrisentan

This product is a key synthetic intermediate of ambrisentan [A2966] which is a highly selective Endothelin-A (ETA) receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH).

References

  • Multistep process for preparation of ambrisentan and darusentan
    • R. M. Satyanarayana, C. Nagaraju, A. K. Ramprasad, WO/2010/070658.
  • Process for preparation of ambrisentan from (S)-2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid and a 4,6-dimethylpyrimidine derivative
    • R. M. Gidwani, C. Janssen, A. Mathieu, W. Albrecht, F. Lehmamnn, WO/2010/091877.
  • Rapid determination of ambrisentan enantiomers by enantioselective liquid chromatography using cellulose-based chiral stationary phase in reverse phase mode
  • LC-MS/MS characterization of forced degradation products of ambrisentan: development and validation of a stability-indicating RP-HPLC method


Application
A Synthetic Intermediate of Endothelin Receptor Antagonists

This reagent is used for synthesis of endothelin receptor antagonists, such as darusentan [CAS: 171714-84-4].

References


PubMed Literature


Articles/Brochures

TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.